870640-62-3

Basic information

• Product Name: (2S,3 S)-2-[benzyl(methyl)amino]-3-methylpentan-1-ol
• Synonyms: (2S,3 S)-2-[benzyl(methyl)amino]-3-methylpentan-1-ol
• CAS NO: 870640-62-3
• Molecular Weight: 221.343
• Mol File: 870640-62-3.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: (2S,3 S)-2-[benzyl(methyl)amino]-3-methylpentan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3 S)-2-[benzyl(methyl)amino]-3-methylpentan-1-ol(870640-62-3)
• EPA Substance Registry System: (2S,3 S)-2-[benzyl(methyl)amino]-3-methylpentan-1-ol(870640-62-3)

Safety Data

• Hazardous Substances Data: 870640-62-3(Hazardous Substances Data)

Usage

Description

(2S,3S)-2-[benzyl(methyl)amino]-3-methylpentan-1-ol is a chiral chemical compound with the molecular formula C14H23NO. It is characterized by the presence of a benzyl group, a methyl group, an amino group, and a hydroxyl group, making it a versatile building block for various organic reactions and syntheses. (2S,3 S)-2-[benzyl(methyl)amino]-3-methylpentan-1-ol is commonly used in pharmaceutical research and drug synthesis due to its unique structural features and potential applications.

Uses

Used in Pharmaceutical Research and Drug Synthesis:
(2S,3S)-2-[benzyl(methyl)amino]-3-methylpentan-1-ol is used as a chiral building block for the development of new pharmaceutical compounds. Its unique structural features, including the presence of a benzyl group, a methyl group, an amino group, and a hydroxyl group, make it a valuable component in the synthesis of various drugs and medicinal agents.
Used in Organic Reactions:
(2S,3S)-2-[benzyl(methyl)amino]-3-methylpentan-1-ol is used as a versatile reactant in various organic reactions. Its functional groups, such as the benzyl, methyl, amino, and hydroxyl groups, allow it to participate in a wide range of chemical transformations, making it a useful compound for the synthesis of complex organic molecules.
Used in Chiral Chemistry:
(2S,3S)-2-[benzyl(methyl)amino]-3-methylpentan-1-ol is used as a chiral compound in the study and development of enantioselective reactions and processes. Its non-superimposable mirror image allows researchers to explore the effects of chirality on the reactivity and selectivity of chemical reactions, leading to advancements in the field of asymmetric synthesis and enantioselective catalysis.

Upstream product

• 1859-49-0 (2S,3S)-2-(benzylamino)-3-methylpentanoic acid 
• 100-52-7 benzaldehyde 
• 73-32-5 L-isoleucine 
• 658691-27-1 C₁₃H₁₇NO₂ 
• 4125-97-7 (2S,3S)-2-(benzyl(methyl)amino)-3-methylpentanoic acid 

Downstream Products

• 870640-63-4 (2S,3S)-2-(benzyl(methyl)amino)-3-methylpentanal 
• 870640-61-2 (2S,3S)-N-benzyl-1,1-dimethoxy-N,3-dimethylpentan-2-amine 
• 870640-64-5 tert-butyl (3R,4S,5S)-4-[benzyl(methyl)amino]-3-methoxy-5-methyl heptanoate 
• 1438852-21-1 methyl (S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanoate 
• 669074-47-9 methyl (S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-amino-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanoate 
• 120205-48-3 tert-Butyl (3R,4S,5S)-3-methoxy-4-(N-methylamino)-5-methylheptanoate hydrochloride 
• 120205-52-9 tert-butyl (3R,4S,5S)-4-[(2S)-2-[[(benzyloxy)carbonyl]amino]-N,3-dimethylbutanamido]-3-methoxy-5-methylheptanoate 

Relevant articles and documents

CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER

The present invention relates to an antibody-drug-conjugate or pharmaceutical composition comprising the same. From one aspect, the invention relates to an antibody-drug-conjugate (ADC) comprising an antibody consisting of the Trastuzumab or a biosimilar thereof, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment of cancer comprising administering to the subject an effective amount of said antibody-drug-conjugate or composition comprising the same.

IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER

The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug- conjugate for the treatment of cancer.

DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS

The present invention concerns a compound of following formula (I): where: - R1 is H or OH, - R2 is a (C1-C6)alkyl, COOH, COO-((C1-C6)alkyl) or thiazolyl group, - R3 is H or a (C1-C6)alkyl group, and - R4 is: ■ a straight-chain or branched, saturated or unsaturated hydrocarbon group having 1 to 8 carbon atoms substituted by one or more groups chosen from among OH and NR5R6, ■ -(CH2CH2X1)(CH2CH2X2)a2(CH2CH2X3)a3(CH2CH2X4)a4(CH2CH2X5)a5R7, ■ an aryl-(C1-C8)alkyl group substituted by one or more groups chosen from among OH and NR9R10 groups, or ■ a heterocycle-(C1-C8)alkyl group optionally substituted by one or more groups chosen from among (C1-C6)alkyl, OH and NR12R13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.